Released Apr 15, 2022, after the close
10-Q filed Jul 1, 2022, 92 days after period end · 0001140361-22-024669
Q1 2022 · 10-Q
Revenue—
Net Income-$9.38M-$9.38M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$3.50-$3.50 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$6,296,000N/M
Operating Cash Flow-$5,432,000N/M
Free Cash Flowderived-$5,478,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | — | — | $2.39M | $4.83M |
| Net Income | -$9.38M | -$18.52M | -$1.02M | -$313.00K |
| EPS Diluted | -$3.50 | -$0.67 | -$0.06 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR